Navigation Links
New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011
Date:9/26/2011

of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and Company ... Global Healthcare Conference on Thursday, September 17, 2015. ... of Lilly Oncology and Richard Gaynor , M.D., ... for Lilly Oncology, will participate in a fireside chat ... A live audio webcast will be available on the ...
(Date:8/27/2015)... 27, 2015  A mere one in seven new ... Hamilton . A new white paper from ... impeding and disrupting manufacturers, success. The white ... Value In Product Development Processes provides insight into: ... how it affects the product development process resulting in: ...
(Date:8/27/2015)... and TORONTO , Aug. 27, 2015 ... today announced the issuance of a white paper on ... insulin spray product.  The white paper was presented to ... stockholders by Dr. James H. Anderson, Jr. , ... may be viewed online on the Generex website. ...
Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... Calif., March 24 NuRx,Pharmaceuticals, Inc. (OTC Bulletin Board: ... a Phase I clinical trial of the first-in-class,rexinoid receptor ... expects to complete in the fourth,quarter of this year, ... compound. NRX4204 is the company,s first drug candidate in ...
... March 22 Issue of The Lancet -, ... announced that efficacy results of the randomized ... the March 22 issue of The Lancet ... in,combination with 5-fluorouracil/leucovorin (5-FU/LV), a chemotherapy,regimen called ...
Cached Medicine Technology:NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 3Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 4Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 5
(Date:8/27/2015)... ... August 27, 2015 , ... ... that its Krames Patient Education content is ICD-10 ready and available to all ... the new ICD-10 code sets, which are more targeted and return a more ...
(Date:8/27/2015)... ... 2015 , ... In addition to its existing Doctor of Philosophy in Leadership ... at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor ... practice nurses for the highest level of clinical nursing practice. , “Our vision ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... Analysis signed a partnership agreement for quality market research promotion on the ... by Black Swan Analysis. , Commenting on the partnership agreement, Natalie Aster, ...
(Date:8/27/2015)... ... ... Sunbelt® Bakery, maker of delicious granola snacks that have a bakery-fresh taste with ... bars should taste with the launch of its new line of protein bars that ... , The new Protein Delights are individually wrapped wafer bars that also contain ...
(Date:8/27/2015)... Ca (PRWEB) , ... August 27, 2015 , ... ... Southern California including Los Angeles, Riverside, San Bernardino, and Orange County. ... Healthpointe’s executive physical exams are offered annually at all of its locations. ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3Health News:Healthpointe Now Offering Executive Physicals 2
... March 4 STAAR Surgical,Company (Nasdaq: STAA ... invasive ophthalmic products, congratulates Dr. Brian Boxer,Wachler on ... this morning,correcting NBCSports.com columnist Alan Abrahamson,s vision with ... the only foldable, minimally invasive lens approved,in the ...
... schools participate in 6th annual KID,HEALTHY--Steps to Healthy ... To combat the,rising trend of childhood obesity ... fifth grade students and parents from Los Angeles,Orange, ... schools and,after-school programs will participate in the KID ...
... acute kidney injury (AKI), an external device containing human ... significantly reduces the risk of death, according to a ... the American Society of Nephrology. , The experimental renal ... desperately ill patients with AKI. "Deployment of the ...
... Argosy Publishing, an award-winning interactive, visual content ... www.visiblebody.com ), the first free, Web-based 3-D interactive ... developed for educators, and health and medical professionals, ... that demonstrates how the human body works. It ...
... Spring Forward - it,s National Sleep Awareness Week, ... physician and,providers at Swedish Medical Center have transitioned ... Sleep Medicine Associates. The new medical group,founded by ... Swedish,Sleep Medicine Institute, will initially operate two centers ...
... the Wildlife Conservation Society, the BioDiversity Research Institute, ... environmental mercurymuch of which comes from human-generated emissionsis ... common loons in the Northeast. , The ... symbolic of northern lakes and wildernessappear in the ...
Cached Medicine News:Health News:STAAR Surgical's Visian ICL Procedure Performed Live on NBC's Today show 2Health News:STAAR Surgical's Visian ICL Procedure Performed Live on NBC's Today show 3Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 2Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 3Health News:'Renal Assist Device' reduces risk of death from acute kidney failure 2Health News:Argosy publishing launches The Visible Body 2Health News:Argosy publishing launches The Visible Body 3Health News:Sleep Medicine Associates Opens New Doors at Swedish - Cherry Hill Campus 2Health News:Scientists find mercury threatens next generation of loons 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: